Lakefront Biotherapeutics (LKFT) Net Margin (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Net Margin data on file, last reported at 223.61% in Q1 2026.

• Net Margin for Q1 2026 came in at 223.61%, up 42821.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 76.5% (up 12515.0% YoY), and the FY2025 annual result was 28.85%, up 197.0% from the prior year.
• Net Margin climbed to 223.61% in Q1 2026 per LKFT's latest filing, from 86.83% in the prior quarter.
• Over five years, Net Margin peaked at 223.61% in Q1 2026 and troughed at 204.6% in Q1 2025.
• A 5-year average of 29.41% and a median of 9.24% in 2022 frame the typical range for Net Margin.
• The sharpest annual moves came in 2025 and 2026: Net Margin slumped 34911 bps in 2025, then soared 42821 bps in 2026.
• A 5-year view of Net Margin shows it stood at 122.67% in 2022, then sank by 76 bps to 28.97% in 2023, then surged by 133 bps to 67.49% in 2024, then increased by 29 bps to 86.83% in 2025, then soared by 158 bps to 223.61% in 2026.
• Business Quant data shows LKFT's Net Margin at 223.61% in Q1 2026, 86.83% in Q4 2025, and 2.65% in Q3 2025.